Literature DB >> 34304247

Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR.

Sena Kim1, Kidist Ashami1, Sora Lim1, Karl Staser1,2, Kiran Vij1, Srikanth Santhanam3, Julie Ritchey1, Sarah Peterson1, Feng Gao4, Matthew A Ciorba3, Matthew L Cooper1, John F DiPersio1, Jaebok Choi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34304247      PMCID： PMC8732299          DOI： 10.1038/s41375-021-01360-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  15 in total

1.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

Review 2.  The role of Stat5a and Stat5b in signaling by IL-2 family cytokines.

Authors:  J X Lin; W J Leonard
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 3.  Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.

Authors:  James Lm Ferrara; Christopher M Smith; Julia Sheets; Pavan Reddy; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808

Review 4.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

5.  Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.

Authors:  R Moriggl; D J Topham; S Teglund; V Sexl; C McKay; D Wang; A Hoffmeyer; J van Deursen; M Y Sangster; K D Bunting; G C Grosveld; J N Ihle
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

6.  Selective targeting of α4β1 integrin attenuates murine graft versus host disease.

Authors:  Bader Alahmari; Matthew L Cooper; Kiran Vij; Julie Ritchey; Peter Ruminski; Feng Gao; Jaebok Choi; John F DiPersio
Journal:  Leukemia       Date:  2020-03-09       Impact factor: 11.528

7.  Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD.

Authors:  Kidist Ashami; John F DiPersio; Jaebok Choi
Journal:  Oncotarget       Date:  2018-11-06

8.  Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.

Authors:  C Castilla-Llorente; P J Martin; G B McDonald; B E Storer; F R Appelbaum; H J Deeg; M Mielcarek; H Shulman; R Storb; R A Nash
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

9.  Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.

Authors:  Jaebok Choi; Matthew L Cooper; Bader Alahmari; Julie Ritchey; Lynne Collins; Matthew Holt; John F DiPersio
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

10.  Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.

Authors:  Jaebok Choi; Matthew L Cooper; Karl Staser; Kidist Ashami; Kiran R Vij; Bing Wang; Lynne Marsala; Jessica Niswonger; Julie Ritchey; Bader Alahmari; Samuel Achilefu; Ikuo Tsunoda; Mark A Schroeder; John F DiPersio
Journal:  Leukemia       Date:  2018-04-02       Impact factor: 11.528
View more
  3 in total

1.  Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.

Authors:  Stephen P Persaud; Julie K Ritchey; Sena Kim; Sora Lim; Peter G Ruminski; Matthew L Cooper; Michael P Rettig; Jaebok Choi; John F DiPersio
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

Review 2.  Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

Review 3.  T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.

Authors:  Hua Jiang; Denggang Fu; Alan Bidgoli; Sophie Paczesny
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.